Bioventus (BVS) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue grew 15% year-over-year to $139 million, marking the fourth consecutive quarter of double-digit organic growth.

• Raised full-year revenue guidance to the high end of previous expectations, reflecting strong execution across all business segments.

• Announced divestiture of Advanced Rehabilitation Business for $25 million plus up to $20 million in earnouts, expected to close by year-end or early 2025.

• Net loss from continuing operations narrowed to $5.4 million in Q3, with improved adjusted EBITDA and cash flow.

• Focused on accelerating revenue growth, improving profitability, and enhancing liquidity.

Financial highlights

• Q3 revenue reached $139 million, up 15% year-over-year, with U.S. sales up 15.7% and international sales up 10.2%.

• Adjusted EBITDA was $23.6 million, up 8% from prior year; adjusted net income rose 10% to $5 million; adjusted EPS was $0.06.

• Gross margin improved to 67.3% GAAP and 74.7% non-GAAP in Q3.

• Ended Q3 with $43.1 million in cash and $345 million in long-term debt.

• Net cash from operating activities for Q3 was $10.3 million, up from negative $8.3 million in Q3 2023.

Outlook and guidance

• Full-year 2024 net sales guidance raised to $562–$567 million, with adjusted EPS guidance increased to $0.40–$0.42 and adjusted EBITDA guidance at $104–$107 million.

• Expect to end 2024 with zero balance on the revolver, repaid with cash and Q4 free cash flow.

• Projecting double-digit cash flow from operations in Q4 and a significant increase in 2025.

• Targeting net leverage below 3x in 2025, with continued margin expansion of at least 100 basis points annually.

• Management expects current cash, operating cash flows, and credit facility access to be sufficient for at least 12 months.